1. A method of treating HIV, comprising administering, to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient
without food or under a fasting condition, and wherein said dosage form comprises a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising at least one pharmaceutically acceptable water-soluble polymer and at
least one pharmaceutically acceptable surfactant, wherein said surfactant is sorbitan monolaurate, and said water-soluble polymer has a Tg of at least 50.degree. C.

2. The method of claim 1, wherein each of said at least one pharmaceutically acceptable water-soluble polymer has a Tg of at least 50.degree. C.

3. The method of claim 2, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises a copolymer of N-vinyl pyrrolidone and vinyl acetate.

5. The method of claim 1, wherein said dosage form comprises a solid solution of lopinavir and ritonavir in said matrix.

6. The method of claim 5, wherein each of said at least one pharmaceutically acceptable water-soluble polymer has a Tg of at least 50.degree. C. and each of said at least one pharmaceutically acceptable surfactant has an HLB value of from 4 to
10.

7. The method of claim 6, wherein said at least one pharmaceutically acceptable surfactant accounts for at least 50% by weight of the total amount of surfactants comprised in said dosage form.

8. The method of claim 6, wherein said dosage form comprises from 50 to 85% by weight of the dosage form of said at least one pharmaceutically acceptable water-soluble polymer, and from 2 to 20% by weight of the dosage form of said at least one
pharmaceutically acceptable surfactant.

9. The method of claim 8, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises a copolymer of N-vinyl pyrrolidone and vinyl acetate.

10. The method of claim 8, wherein said at least one pharmaceutically acceptable water-soluble polymer is copovidone.

11. A method of treating HIV, comprising administering to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and said dosage form comprises
a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising sorbitan monolaurate and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., and wherein when said dosage form is
dissolved in vitro using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POEIOLE (Polyoxyethylene 10 Lauryl Ether) medium at 37.degree. C., 20% to 30% of lopinavir in said dosage form is released from 0 to 15 minutes, or 43% to 63 % of lopinavir in
said dosage form is released from 15 to 30 minutes, or 61.3% to 81.7% of lopinavir in said dosage form is released from 30 to 45 minutes, or 75.4% to 93.2% of lopinavir in said dosage form is released from 45 to 60 minutes, and wherein when said dosage
form is dissolved in vitro using a USP apparatus 2 (paddle) at 75 rpm with a 0.06M POE10LE (Polyoxyethylene 10 Lauryl Ether) medium at 37.degree. C., from 19.8% to 34.4% of ritonavir in said dosage form is released from 0 to 15 minutes, or from 41.6% to
76.5% of ritonavir in said dosage form is released from 15 to 30 minutes, or from 59.4% to 91.1% of ritonavir in said dosage form is released from 30 to 45 minutes, or from 73.4% to 95% of ritonavir in said dosage form is released from 45 to 60 minutes.

12. A method of treating HIV, comprising administering to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and said dosage form comprises
a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising sorbitan monolaurate and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., and wherein upon administration of
said dosage form to each member of a study population, the mean of lopinavir AUC.infin. (fed) over lopinavir AUC.infin. (fasted) ratios for all members of the study population is from 0.7 to 1.43.

13. A method of treating HIV, comprising administering to a patient in need thereof a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food or under a fasting condition, and said dosage form comprises
a solid solution or solid dispersion of lopinavir and ritonavir in a matrix, said matrix comprising sorbitan monolaurate and a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C., and wherein upon administration of
said dosage form to each member of a study population, the mean of lopinavir Cmax (fed) over lopinavir Cmax (fasted) ratios for all members of the study population is from 0.7 to 1.43.

14. A method of treating an HIV patient, comprising administering to said patient a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food, wherein said dosage form comprises at least one HIV protease
inhibitor formulated in solid solution, said solid solution comprising at least one pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. and sorbitan monolaurate, and wherein said at least one HIV protease inhibitor
comprises lopinavir and ritonavir.

15. The method of claim 14, wherein each of said at least one pharmaceutically acceptable water-soluble polymer has a Tg of at least 50.degree. C..

16. The method of claim 15, wherein said at least one pharmaceutically acceptable water-soluble polymer comprises a copolymer of N-vinyl pyrrolidone and vinyl acetate.

17. The method of claim 15, wherein said dosage form comprises from 50 to 85% by weight of the dosage form of said at least one pharmaceutically acceptable water-soluble polymer, and from 2 to 20% by weight of the dosage form of said sorbitan
monolaurate.

18. The method of claim 17, wherein said at least one pharmaceutically acceptable water-soluble polymer is copovidone.

19. A method of treating an HIV patient, comprising administering to said patient a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food, wherein said dosage form comprises ritonavir and lopinavir
formulated in solid solution or solid dispersion, said solid solution or solid dispersion comprising a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. and sorbitan monolaurate.

20. The method of claim 19, wherein said water-soluble polymer is copolymer of N-vinyl pyrrolidone and vinyl acetate.

21. A method of claim 20, wherein said ritonavir and lopinavir are present in an amount from 5% to 30% by weight of the dosage form, said copolymer of N-vinyl pyrrolidone and vinyl acetate is present from 50% to 85% by weight of the dosage
form, and said sorbitan monolaurate is present from 2% to 20% by weight of the dosage form.

22. The method of claim 19, wherein said water-soluble polymer is copovidone.

24. The method of claim 22, wherein said solid solution or solid dispersion is a solid solution.

25. The method of claim 19, wherein said solution or solid dispersion is solid solution.

26. The method of claim 21, wherein said solution or solid dispersion is solid solution.

27. The method of claim 26, wherein said water soluble polymer is copovidone.

28. The method of claim 23, wherein said solution or solid dispersion is solid solution.

29. A method of treating an HIV patient, comprising administering to said patient a solid pharmaceutical dosage form, wherein said dosage form is taken by said patient without food, wherein said dosage form comprises ritonavir and lopinavir
formulated in solid solution or solid dispersion, said solid solution or solid dispersion comprising a pharmaceutically acceptable water-soluble polymer having a Tg of at least 50.degree. C. and sorbitan monopalmitate.

30. The method of claim 29, wherein said water-soluble polymer is copolymer of N-vinyl pyrrolidone and vinyl acetate.

31. A method of claim 30, wherein said ritonavir and lopinavir are present in an amount from 5% to 30% by weight of the dosage form, said copolymer of N-vinyl pyrrolidone and vinyl acetate is present from 50% to 85% by weight of the dosage
form, and said sorbitan monopalmitate is present from 2% to 20% by weight of the dosage form.

32. The method of claim 31, wherein said water-soluble polymer is copovidone.

33. The method of claim 29, wherein said solid solution or solid dispersion is solid solution.

34. The method of claim 31, wherein said solid solution or solid dispersion is solid solution.

35. The method of claim 32, wherein said solution or solid dispersion is solid solution.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.